{
    "id": 23681,
    "fullName": "PTEN Y86fs",
    "impact": "frameshift",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "PTEN Y86fs results in a change in the amino acid sequence of the Pten protein beginning at aa 86 of 403, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the C2 tensin-type domain, Y86fs is predicted to result in a loss of Pten protein function (UniProt.org).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5728,
        "geneSymbol": "PTEN",
        "terms": [
            "PTEN",
            "10q23del",
            "BZS",
            "CWS1",
            "DEC",
            "GLM2",
            "MHAM",
            "MMAC1",
            "PTEN1",
            "PTENbeta",
            "TEP1"
        ]
    },
    "variant": "Y86fs",
    "createDate": "06/24/2016",
    "updateDate": "09/10/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7082,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient harboring PTEN Y86fs and BRAF V600X developed the resistance-associated mutation, PIK3CA H1047R, after treatment with Zelboraf (vemurafenib) (PMID: 24265153).",
            "molecularProfile": {
                "id": 24398,
                "profileName": "BRAF V600X PIK3CA H1047R PTEN Y86fs"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24397,
            "profileName": "PTEN Y86fs",
            "profileTreatmentApproaches": [
                {
                    "id": 13505,
                    "name": "PIK3CB inhibitor",
                    "profileName": "PTEN Y86fs"
                },
                {
                    "id": 13504,
                    "name": "Akt Inhibitor (Pan)",
                    "profileName": "PTEN Y86fs"
                },
                {
                    "id": 13503,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "PTEN Y86fs"
                },
                {
                    "id": 13506,
                    "name": "Akt1 Inhibitor",
                    "profileName": "PTEN Y86fs"
                },
                {
                    "id": 13507,
                    "name": "Akt2 Inhibitor",
                    "profileName": "PTEN Y86fs"
                }
            ]
        },
        {
            "id": 24398,
            "profileName": "BRAF V600X PIK3CA H1047R PTEN Y86fs",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}